Category: Uncategorized

Stablepharma has partnered with the University of Strathclyde to advance their COVID mRNA vaccine thermo-stabilisation technology following positive recent COVID mRNA stability data Bath, UK, 14 July 2021: A British breakthrough invention could form a crucial part in the urgent quest to combat Covid-19 and future virus pandemics. StablevaX™ allows vaccines to be transported and […]

Stablepharma are delighted to announce that Professor Saul Faust has accepted a position on Stablepharma’s Advisory Board. Professor Faust BMA, MBBS, FRCPCH, PhD, FHEA Professor or Paediatric Immunology and Infectious Diseases at the University of Southampton and Director of the NIHR Southampton Clinical Research Facility. He is currently leading the UK national 3rd dose COVID-19 […]

Having read the recent article by Peter Mwai, BBC Reality Check, ‘Covid-19 vaccines: Why some African states can’t use their vaccines’ really saddens and frustrates me as a scientist and I am sure, all of those involved in the creating, manufacturing and delivery of life saving vaccines feel the same. The World Health Organization reports […]

Express Pharma highlights the significant amount of H2020 funding that has helped UK Bio/Pharma companies advance their innovative technologies – Stablepharma Ltd received €50,000 to further develop its StablevaX™ technology. Full article can be found here.  Through the Brexit deal struck between the UK and EU on 24 December 2021, the UK will be part […]

As featured in Manufacturing Chemist publication 30th Mar 2021. https://www.manufacturingchemist.com/news/article_page/Stablepharma_and_BB-NCIPD_collaborating_on_thermally_stable_vaccine/175613 The companies are developing a version of BB-NCIPD’s Td vaccine using Stablepharma’s StablevaX technology Stablepharma has announced a collaboration with European vaccine manufacturer BB-NCIPD (Bul Bio), to develop a thermally stable version of the Tetanus diphtheria (Td) vaccine using the patented StablevaX formulation and device. […]

Excerpts of an article featured on Chemistry World publication, 19th January 2021; click here to read the full article. As the world celebrates the arrival of vaccines to protect against Covid-19, the logistics of distributing them is under the spotlight as never before. It’s a delicate balancing act – both heat and excessive cold damage […]

UK based Stablepharma is delighted to announce that they have been awarded an Innovate UK Smart Grant to advance the development of their disruptive vaccine stabilisation technology, StablevaX™. “This is a very welcome endorsement of our innovative technology to thermally stabilise vaccines”, says Nick Child, Managing Director, Stablepharma Ltd. This innovative technology will enable vaccines […]

Stablepharma Ltd is delighted to announce that the StablevaX™ invention to thermally stabilise vaccines, has just been granted a patent by the USPTO in the United States of America. This is probably the companies most commercially important patent granted to date and now completes our portfolio of successful grants in 14 international jurisdictions. Nick Child, […]

Dr Bruce Roser was featured in a recent piece from the Pharma Technology publication addressing the manufacturing and logistic challenges facing the worldwide deployment of a COVID-19 vaccine. See an excerpt below, and read the full article here. “UK-based Stablepharma has come up with a solution for stabilised vaccines so that they are no longer […]

The biggest problem with medicines is how they are stored, where they are stored and their use by dates and with an ongoing global pandemic this is an issue we will face when a COVID-19 vaccine is found. Irish Tech News talk to Dr Bruce Roser the founder and chairman of Stablepharma whose StablevaX technology […]